Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling

• Published in: Antimicrobial agents and chemotherapy Vol. 66; no. 3; p. e0220321
• Main Authors: Bilal, Hajira, Tait, Jessica R, Lang, Yinzhi, Zhou, Jieqiang, Bergen, Phillip J, Peleg, Anton Y, Bulitta, Jürgen B, Oliver, Antonio, Nation, Roger L, Landersdorfer, Cornelia B
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 15.03.2022
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antimicrobial Chemotherapy; Biofilms; Ceftazidime - pharmacology; Ceftazidime - therapeutic use; Humans; Microbial Sensitivity Tests; Pharmacology; Pseudomonas aeruginosa; Pseudomonas Infections - drug therapy; Pseudomonas Infections - microbiology; Tobramycin - pharmacology; Tobramycin - therapeutic use; mathematical modeling; pharmacokinetics; Pseudomonas aeruginosa; dosage regimen optimization; dynamic infection model; pharmacodynamics
• DOI: 10.1128/aac.02203-21
• ISSN: 0066-4804

Acute exacerbations of chronic respiratory infections in patients with cystic fibrosis are highly challenging due to hypermutable Pseudomonas aeruginosa, biofilm formation and resistance emergence. We aimed to systematically evaluate the effects of intravenous versus inhaled tobramycin (TOB) with and without intravenous ceftazidime (CAZ). Two hypermutable P. aeruginosa isolates, CW30 (MIC , 0.5 mg/liter; MIC , 2 mg/liter) and CW8 (MIC , 2 mg/liter; MIC , 8 mg/liter), were investigated for 120 h in dynamic biofilm studies. Treatments were intravenous ceftazidime, 9 g/day (33% lung fluid penetration); intravenous tobramycin, 10 mg/kg of body every 24 h (50% lung fluid penetration); inhaled tobramycin, 300 mg every 12 h; and both ceftazidime-tobramycin combinations. Total and less susceptible planktonic and biofilm bacteria were quantified over 120 h. Mechanism-based modeling was performed. All monotherapies were ineffective for both isolates, with regrowth of planktonic (≥4.7 log CFU/ml) and biofilm (>3.8 log CFU/cm ) bacteria and resistance amplification by 120 h. Both combination treatments demonstrated synergistic or enhanced bacterial killing of planktonic and biofilm bacteria. With the combination simulating tobramycin inhalation, planktonic bacterial counts of the two isolates at 120 h were 0.47% and 36% of those for the combination with intravenous tobramycin; for biofilm bacteria the corresponding values were 8.2% and 13%. Combination regimens achieved substantial suppression of resistance of planktonic and biofilm bacteria compared to each antibiotic in monotherapy for both isolates. Mechanism-based modeling well described all planktonic and biofilm counts and indicated synergy of the combination regimens despite reduced activity of tobramycin in biofilm. Combination regimens of inhaled tobramycin with ceftazidime hold promise to treat acute exacerbations caused by hypermutable P. aeruginosa strains and warrant further investigation.